FDA Eases Oversight on Wearables and AI-Enabled Devices to Accelerate Innovation
In an effort to encourage innovation and adoption of digital health products, the FDA will reduce regulatory burdens on wearables and AI-powered devices, marking a strategic departure from past stringent oversight.
FDA's New Regulation Approach
- The FDA plans to deregulate a broad array of digital health products including AI-enabled medical devices and wearables.
- The initiative seeks to foster widespread use of AI in healthcare technology.
Implications
- This move reflects an evolving regulatory perspective balancing innovation with safety.
- Could accelerate development and market entry of AI-based health solutions.
Source: STAT News
Join the BioIntel newsletter
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.